Both in Diagnostics
Myriad Genetics vs Insight Molecular Diagnostics
Over the past year MYGN returned −27.0% and IMDX returned −56.0%; their daily moves had a correlation of 0.09.
MYGN −27.0% IMDX −56.0%Growth of $1, one year, split-adjusted
| Metric | MYGN | IMDX |
|---|---|---|
| Price | $5.97 | $2.69 |
| Market cap | $571.0M | $88.0M |
| Today | −1.16% | −1.82% |
| 1 month | +39.5% | −20.4% |
| 6 months | +45.3% | −46.5% |
| Year to date | −2.9% | −64.1% |
| 1 year | −27.0% | −56.0% |
| Revenue growth (YoY) | −10.5% | −53.9% |
| Gross margin | 66.6% | 65.7% |
| Net margin | −22.7% | −4711.3% |
| P/E (TTM) | — | — |
| Price / sales | 0.7× | 52.7× |
| Net cash | -$5.5M | $17.8M |
| Dividend yield | — | — |
| Volatility (60d) | 85.1% | 94.7% |
| Short % of float | 10.1% | 3.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).